Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment symbols : Hznp save search
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
Published: 2023-09-29 (Crawled : 23:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: -0.05%
tepezza disease treatment thyroid eye
TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2023-06-26 (Crawled : 18:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.43%
H: 0.48%
C: 0.38%
tepezza disease active approved treatment thyroid brazil eye
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2023-06-22 (Crawled : 12:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.25%
H: 0.75%
C: 0.04%
tepezza disease active japan positive treatment thyroid topline eye trial therapeutics
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
Published: 2023-05-02 (Crawled : 16:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.04%
H: 0.04%
C: -0.21%
lupus treatment trial therapeutics phase 2
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population
Published: 2023-01-18 (Crawled : 14:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: -0.22%
treatment trial therapeutics study
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
Published: 2023-01-04 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.01%
H: 0.13%
C: -0.03%
treatment lupus trial therapeutics phase 2
UPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Published: 2022-12-20 (Crawled : 15:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.03%
H: 0.21%
C: 0.03%
uplizna treatment brazil approved
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Published: 2022-12-08 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.26%
H: 2.62%
C: 0.37%
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: 0.85%
H: 0.6%
C: -4.77%
hzn-457 treatment trial phase 1
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Published: 2022-12-08 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.26%
H: 2.62%
C: 0.37%
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: 0.85%
H: 0.6%
C: -4.77%
hzn-457 treatment trial therapeutics phase 1
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2022-11-16 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.04%
H: 1.08%
C: -0.54%
tepezza treatment thyroid disease active japan eye trial therapeutics
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint
Published: 2022-09-12 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 1.57%
H: 1.42%
C: -0.67%
treatment trial therapeutics phase 2
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.5%
H: 2.01%
C: 1.79%
hzn-7734 treatment trial therapeutics enroll phase 2
Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Published: 2022-05-02 (Crawled : 09:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -3.78%
H: 0.8%
C: 0.33%
uplizna treatment approval therapeutics
Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2022-02-23 (Crawled : 19:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.97%
H: 0.38%
C: -2.35%
treatment eye eye disease trial therapeutics disease active phase 3
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Published: 2022-01-24 (Crawled : 13:30) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -2.11%
H: 2.77%
C: 2.72%
hzn-825 treatment phase 2 fibrosis phase 2b trial therapeutics enroll
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Published: 2021-11-09 (Crawled : 15:15) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.16%
H: 0.46%
C: -0.68%
treatment phase 2 sclerosis phase 2b trial enroll
New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Published: 2021-10-04 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.5%
H: 2.54%
C: 1.45%
multiple sclerosis treatment sclerosis
Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED)
Published: 2021-09-07 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.2%
H: 0.59%
C: -1.08%
disease treatment eye eye disease trial
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus
Published: 2021-06-29 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.08%
H: 0.66%
C: -0.95%
treatment phase 2 trial lupus enroll
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.